The Journey to a Respiratory Syncytial Virus Vaccine

Overview

Journal Ann Allergy Asthma Immunol

Specialties Allergy & Immunology
Pulmonary Medicine

Date 2020 Mar 29

PMID 32217187

Citations 63

Authors

Asuncion Mejias

Rosa Rodriguez-Fernandez

Silvia Oliva

Mark E Peeples

Octavio Ramilo

Affiliations

Soon will be listed here.

Abstract

Objective: The high burden associated with respiratory syncytial virus (RSV) has made the development of RSV vaccine(s) a global health high priority. This review summarizes the journey to an RSV vaccine, the different strategies and challenges associated with the development of preventive strategies for RSV, and the diverse products that are undergoing clinical testing.

Data Sources: Studies on RSV biology, immunology, epidemiology, and monoclonal antibodies (mAbs) and vaccines were searched using MEDLINE. We also searched PATH.org and ClinicalTrials.gov for updated information regarding the status of RSV vaccines and mAbs undergoing clinical trials.

Study Selections: We selected relevant studies conducted in infants and young children, pregnant women, and elderly population for the prevention of RSV infection.

Results: Identification of a safe and immunogenic vaccine has been an important but elusive initiative for more than 60 years for different reasons, including the legacy of formalin-inactivated vaccine, our limited understanding of the immune response to RSV and how it relates to clinical disease severity, or the need for different end points according to the different vaccine platforms. Nevertheless, there are currently 39 vaccines and mAbs under development and 19 undergoing clinical trials.

Conclusion: Over the past decade, there have been significant advances in our knowledge of RSV molecular and structural biology and in understanding the human immune response to RSV. Despite the barriers, there are several promising mAbs and RSV vaccines undergoing clinical trials that hope to offer protection to the most vulnerable populations.

Citing Articles

Burden of Respiratory Syncytial Virus Disease in Adults with Asthma and Chronic Obstructive Pulmonary Disease: A Systematic Literature Review.

Penders Y, Brusselle G, Falsey A, Rohde G, Betancur E, Guardado M Curr Allergy Asthma Rep. 2025; 25(1):14.

PMID: 39994162 PMC: 11850418. DOI: 10.1007/s11882-025-01194-w.

Molecular epidemiology and phylogenetic analysis of human respiratory syncytial virus type B in Riyadh, Saudi Arabia.

Aljowaie R, Farrag M, Abalkhail T, Aziz I, Almuqrin A, Alkubaisi N Virus Genes. 2025; .

PMID: 39966224 DOI: 10.1007/s11262-025-02143-5.

A truncated pre-F protein mRNA vaccine elicits an enhanced immune response and protection against respiratory syncytial virus.

Lin M, Yin Y, Zhao X, Wang C, Zhu X, Zhan L Nat Commun. 2025; 16(1):1386.

PMID: 39910047 PMC: 11799228. DOI: 10.1038/s41467-025-56302-1.

[Interpretation of "Expert recommendations for the prevention of common respiratory viral infections in neonates": problems faced by respiratory syncytial virus infection in neonates].

Cheng C, Wang Y, Shi Y Zhongguo Dang Dai Er Ke Za Zhi. 2025; 27(1):26-32.

PMID: 39825648 PMC: 11750237. DOI: 10.7499/j.issn.1008-8830.2409033.

Respiratory Syncytial Virus: A WAidid Consensus Document on New Preventive Options.

Ricco M, Abu-Raya B, Icardi G, Spoulou V, Greenberg D, Pecurariu O Vaccines (Basel). 2025; 12(12.

PMID: 39771979 PMC: 11679680. DOI: 10.3390/vaccines12121317.

References

Jain S, Williams D, Arnold S, Ampofo K, Bramley A, Reed C . Community-acquired pneumonia requiring hospitalization among U.S. children. N Engl J Med. 2015; 372(9):835-45. PMC: 4697461. DOI: 10.1056/NEJMoa1405870. View

Roberts S, Compans R, Wertz G . Respiratory syncytial virus matures at the apical surfaces of polarized epithelial cells. J Virol. 1995; 69(4):2667-73. PMC: 188952. DOI: 10.1128/JVI.69.4.2667-2673.1995. View

Mazur N, Higgins D, Nunes M, Melero J, Langedijk A, Horsley N . The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates. Lancet Infect Dis. 2018; 18(10):e295-e311. DOI: 10.1016/S1473-3099(18)30292-5. View

Larranaga C, Ampuero S, Luchsinger V, Carrion F, Aguilar N, Morales P . Impaired immune response in severe human lower tract respiratory infection by respiratory syncytial virus. Pediatr Infect Dis J. 2009; 28(10):867-73. DOI: 10.1097/INF.0b013e3181a3ea71. View

Hause A, Avadhanula V, Maccato M, Pinell P, Bond N, Santarcangelo P . Clinical characteristics and outcomes of respiratory syncytial virus infection in pregnant women. Vaccine. 2019; 37(26):3464-3471. PMC: 7126758. DOI: 10.1016/j.vaccine.2019.04.098. View

Hall C, Long C, Schnabel K . Respiratory syncytial virus infections in previously healthy working adults. Clin Infect Dis. 2001; 33(6):792-6. DOI: 10.1086/322657. View

McLellan J, Yang Y, Graham B, Kwong P . Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes. J Virol. 2011; 85(15):7788-96. PMC: 3147929. DOI: 10.1128/JVI.00555-11. View

Chaw L, Kamigaki T, Burmaa A, Urtnasan C, Od I, Nyamaa G . Burden of Influenza and Respiratory Syncytial Virus Infection in Pregnant Women and Infants Under 6 Months in Mongolia: A Prospective Cohort Study. PLoS One. 2016; 11(2):e0148421. PMC: 4746066. DOI: 10.1371/journal.pone.0148421. View

Bailey E, Zemke J, Choi J, Gray G . A Mini-Review of Adverse Lung Transplant Outcomes Associated With Respiratory Viruses. Front Immunol. 2020; 10:2861. PMC: 6930876. DOI: 10.3389/fimmu.2019.02861. View

10.

OShea M, Ryan M, Hawksworth A, Alsip B, Gray G . Symptomatic respiratory syncytial virus infection in previously healthy young adults living in a crowded military environment. Clin Infect Dis. 2005; 41(3):311-7. DOI: 10.1086/431591. View

11.

Siber G, Leszcynski J, Pena-Cruz V, Anderson R, Hemming V, Walsh E . Protective activity of a human respiratory syncytial virus immune globulin prepared from donors screened by microneutralization assay. J Infect Dis. 1992; 165(3):456-63. DOI: 10.1093/infdis/165.3.456. View

12.

Johnson S, McNally B, Ioannidis I, Flano E, Teng M, Oomens A . Respiratory Syncytial Virus Uses CX3CR1 as a Receptor on Primary Human Airway Epithelial Cultures. PLoS Pathog. 2015; 11(12):e1005318. PMC: 4676609. DOI: 10.1371/journal.ppat.1005318. View

13.

Shay D, Holman R, Newman R, Liu L, Stout J, Anderson L . Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA. 1999; 282(15):1440-6. DOI: 10.1001/jama.282.15.1440. View

14.

Graham B . Vaccine development for respiratory syncytial virus. Curr Opin Virol. 2017; 23:107-112. PMC: 5653266. DOI: 10.1016/j.coviro.2017.03.012. View

15.

Zhu Q, McLellan J, Kallewaard N, Ulbrandt N, Palaszynski S, Zhang J . A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants. Sci Transl Med. 2017; 9(388). DOI: 10.1126/scitranslmed.aaj1928. View

16.

Capella C, Chaiwatpongsakorn S, Gorrell E, Risch Z, Ye F, Mertz S . Prefusion F, Postfusion F, G Antibodies, and Disease Severity in Infants and Young Children With Acute Respiratory Syncytial Virus Infection. J Infect Dis. 2017; 216(11):1398-1406. PMC: 5853469. DOI: 10.1093/infdis/jix489. View

17.

Zhang L, Peeples M, Boucher R, Collins P, Pickles R . Respiratory syncytial virus infection of human airway epithelial cells is polarized, specific to ciliated cells, and without obvious cytopathology. J Virol. 2002; 76(11):5654-66. PMC: 137037. DOI: 10.1128/jvi.76.11.5654-5666.2002. View

18.

Garcia C, Bhore R, Soriano-Fallas A, Trost M, Chason R, Ramilo O . Risk factors in children hospitalized with RSV bronchiolitis versus non-RSV bronchiolitis. Pediatrics. 2010; 126(6):e1453-60. PMC: 3761792. DOI: 10.1542/peds.2010-0507. View

19.

Polack F, Teng M, Collins P, Prince G, Exner M, Regele H . A role for immune complexes in enhanced respiratory syncytial virus disease. J Exp Med. 2002; 196(6):859-65. PMC: 2194058. DOI: 10.1084/jem.20020781. View

20.

Johnson S, Oliver C, Prince G, Hemming V, Pfarr D, Wang S . Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis. 1997; 176(5):1215-24. DOI: 10.1086/514115. View